RxDoctor Payments Data

Christal Joseph, PA

Physician Assistant · Desoto, TXNPI 1396031472

Payments from drug & device makers

$2,451in general payments, 2019–2025

Across 147 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$752
  • GSK$611
  • Regeneron Healthcare Solutions, Inc.$247
  • Boehringer Ingelheim$228
  • Electromed, Inc.$172
  • Sanofi$156
  • plus $285 from 8 others

What the payments were for

  • Food & beverage$2,37197%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,451 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$32,769
Medicare patients
159
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter534$548,594
XolairOmalizumab33$168,874
Fasenra PenBenralizumab25$144,182
Breztri AerosphereBudesonide/Glycopyr/Formoterol147$110,602
Dupixent SyringeDupilumab16$70,831
Stiolto RespimatTiotropium Br/Olodaterol Hcl94$55,192
Spiriva RespimatTiotropium Bromide42$49,540
SymbicortBudesonide/Formoterol Fumarate74$25,411
Breo ElliptaFluticasone/Vilanterol27$17,171
Albuterol Sulfate HfaAlbuterol Sulfate520$15,571
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$13,996
Wixela InhubFluticasone Propion/Salmeterol60$8,720
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$8,340
Azelastine Hcl170$8,298
Qvar RedihalerBeclomethasone Dipropionate11$4,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$611$579,761588 claims
AstraZenecaBreztri Aerosphere, Symbicort$752$136,013221 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$228$104,732136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Desoto

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →